405224-24-0

Basic information

• Product Name: 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE
• Synonyms: 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE;3-Amino-5-bromo-1H-pyrazolo[3,4-B]pyridine;3-Amino-5-bromo-1H-pyrazo...;5-Bromo-1H-pyrazolo[3,4-b]pyridin-3-amine, 3-Amino-7-aza-5-bromo-1H-indazole;1H-Pyrazolo[3,4-b]pyridin-3-aMine,5-broMo-;5-Bromo-1H-pyrazole[3,4-b]pyridin-3-amine;5-bromo-1H-pyrazolo[3,4-b]pyridine-3-amine
• CAS NO: 405224-24-0
• Molecular Formula: C₆H₅BrN₄
• Molecular Weight: 213.03
• Mol File: 405224-24-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 429.136 °C at 760 mmHg
• Flash Point: 213.334 °C
• Appearance: /
• Density: 1.994
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.824
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.55±0.40(Predicted)
• CAS DataBase Reference: 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE(405224-24-0)
• EPA Substance Registry System: 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE(405224-24-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 405224-24-0(Hazardous Substances Data)

Usage

General Description

5-Bromo-1H-pyrazolo[3,4-b]pyridin-3-ylamine is a chemical compound with the molecular formula C8H6BrN5. It is a pyrazolopyridine derivative that is often used as a building block in organic synthesis and medicinal chemistry. 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE contains a bromine atom and a pyrimidinamine moiety, and its structure makes it suitable for use in the development of pharmaceuticals and other biologically active molecules. It may have potential applications in the treatment of various diseases and conditions, and its unique structure makes it a valuable tool for researchers and scientists in the field of drug discovery and development.

InChI:InChI=1/C6H5BrN4/c7-3-1-4-5(8)10-11-6(4)9-2-3/h1-2H,(H3,8,9,10,11)

Upstream product

• 405224-22-8 2-hydroxy-3-cyano-5-bromopyridine 
• 405224-23-9 5-bromo-2-chloropyridine-3-carbonitrile 
• 405224-22-8 5-bromo-2-oxo-1,2-dihydropyridine-3-carbonitrile 

Downstream Products

• 1428799-37-4 5-bromo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine-3-amine 
• 1289183-22-7 2-{(R)-1-[6-(3-amino-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl]ethylamino}-5-cyano-N-[(S)-1-(4-fluorophenyl)ethyl]nicotinamide 
• 1289179-33-4 3-[4-(3-amino-1Η-pyrazolo[3,4-b]pyridin-5-yl)-benzylamino]-6-cyano-pyrazine-2-carboxylic acid [1-(3,4-difluoro-phenyl)-ethyl]-amide 
• 1428799-38-5 C₂₈H₂₈N₆O₂ 
• 1428799-42-1 C₂₀H₂₄BrN₅O 
• 1239467-07-2 C₁₄H₈BrF₃N₄O 
• 1239467-03-8 C₁₄H₁₁BrN₄O 
• 1239467-11-8 C₁₄H₁₁BrN₄O₂ 
• 1239467-12-9 C₁₅H₁₃BrN₄O₃ 
• 1239467-02-7 C₁₄H₁₁BrN₄O 
• 1239467-10-7 C₁₄H₁₁BrN₄O₂ 
• 1239467-04-9 C₁₃H₈BrClN₄O 
• 1239467-01-6 C₁₄H₁₁BrN₄O 

Relevant articles and documents

Pyrazolopyridine hydroxamic acid compound as well as preparation method and application thereof

The invention relates to the technical field of chemical synthesis, in particular to a pyrazolopyridine hydroxamic acid compound as well as a preparation method and application thereof. The pyrazolopyridine hydroxamic acid compound comprises a compound as shown in a formula (1), an isomer thereof, and a hydrate thereof or a pharmaceutically acceptable salt thereof, wherein n is an integer, and R is any one of a substituted or unsubstituted aromatic ring group and a substituted alkyl group. The compound can well inhibit cancer cell proliferation, and then has an excellent treatment effect on tumors.

INDAZOLES

The invention provides novel substituted indazole compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.

A Casein kinase 1/Checkpoint kinase 1 pyrazolo-pyridine protein kinase inhibitor as novel activator of the p53 pathway

Reactivation of the wild-type p53 pathway is one key goal aimed at developing targeted therapeutics in the cancer research field. Although most p53 protein kinases form 'p53-activating' signals, there are few kinases whose action can contribute to the inhibition of p53, as Casein kinase 1 (CK1) and Checkpoint kinase 1 (CHK1). Here we report on a pyrazolo-pyridine analogue showing activity against both CK1 and CHK1 kinases that lead to p53 pathway stabilisation, thus having pharmacological similarities to the p53-activator Nutlin-3. These data demonstrate the emerging potential utility of multivalent kinase inhibitors.